Yahoo Finance selected pharmaceutical firm Novo Nordisk (NVO) as it's 2023 Company of the Year. Developer of obesity medications Wegovy and Ozempic, Novo Nordisk stock has gained over 40% year-to-date. The dramatic uptake of its weight loss injections has fueled speculation about disruptive impacts across sectors like restaurants and food companies.
Yahoo Finance's Brooke DiPalma analyzes Novo Nordisk's selection, investor views on projected market effects, and whether consumer staples face realistic long-term risks from Novo Nordisk's GLP-1 lineup.
About Yahoo Finance:
Yahoo Finance provides free stock ticker data, up-to-date news, portfolio management resources, comprehensive market data, advanced tools, and more information to help you manage your financial life.
- Get the latest news and data at finance.yahoo.com
- Download the Yahoo Finance app on Apple ([ Ссылка ]) or Android ([ Ссылка ])
- Follow Yahoo Finance on social:
X: [ Ссылка ]
Instagram: [ Ссылка ]
TikTok: [ Ссылка ]
Facebook: [ Ссылка ]
LinkedIn: [ Ссылка ]"
#novonordisk #yahoofinance #ozempic
